IL209354A0 - Hydroxy substituted thieno pyrimidinones as melanin concentrating hormone receptor-1 antagonists - Google Patents

Hydroxy substituted thieno pyrimidinones as melanin concentrating hormone receptor-1 antagonists

Info

Publication number
IL209354A0
IL209354A0 IL209354A IL20935410A IL209354A0 IL 209354 A0 IL209354 A0 IL 209354A0 IL 209354 A IL209354 A IL 209354A IL 20935410 A IL20935410 A IL 20935410A IL 209354 A0 IL209354 A0 IL 209354A0
Authority
IL
Israel
Prior art keywords
pyrimidinones
antagonists
hormone receptor
hydroxy substituted
concentrating hormone
Prior art date
Application number
IL209354A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL209354A0 publication Critical patent/IL209354A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL209354A 2008-05-29 2010-11-16 Hydroxy substituted thieno pyrimidinones as melanin concentrating hormone receptor-1 antagonists IL209354A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5694908P 2008-05-29 2008-05-29
PCT/US2009/045452 WO2009146365A1 (en) 2008-05-29 2009-05-28 Hydroxy substituted thieno pyrimidinones as melanin concentrating hormone receptor-1 antagonists

Publications (1)

Publication Number Publication Date
IL209354A0 true IL209354A0 (en) 2011-01-31

Family

ID=41017166

Family Applications (1)

Application Number Title Priority Date Filing Date
IL209354A IL209354A0 (en) 2008-05-29 2010-11-16 Hydroxy substituted thieno pyrimidinones as melanin concentrating hormone receptor-1 antagonists

Country Status (17)

Country Link
US (1) US7989433B2 (cg-RX-API-DMAC7.html)
EP (1) EP2310394A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011521962A (cg-RX-API-DMAC7.html)
KR (1) KR20110021988A (cg-RX-API-DMAC7.html)
CN (1) CN102099360A (cg-RX-API-DMAC7.html)
AR (1) AR075260A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009251331A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0913197A2 (cg-RX-API-DMAC7.html)
CA (1) CA2726264A1 (cg-RX-API-DMAC7.html)
CO (1) CO6280492A2 (cg-RX-API-DMAC7.html)
EA (1) EA201001882A1 (cg-RX-API-DMAC7.html)
IL (1) IL209354A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010012803A (cg-RX-API-DMAC7.html)
PE (1) PE20091928A1 (cg-RX-API-DMAC7.html)
TW (1) TW201000487A (cg-RX-API-DMAC7.html)
WO (1) WO2009146365A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201008451B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851622B2 (en) * 2007-04-25 2010-12-14 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
KR101735868B1 (ko) 2010-02-17 2017-05-15 다케다 야쿠힌 고교 가부시키가이샤 복소고리 화합물
US10406091B2 (en) 2011-12-06 2019-09-10 Conopco, Inc. Skin anti-ageing composition
IL225900A0 (en) * 2013-04-22 2014-03-31 Perrigo Api Ltd A process for the preparation of nicotine that includes the enzymatic reduction of 4-(methylamino)-1-(3-pyridinyl)-1-butanone
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
NZ732573A (en) * 2014-12-30 2019-01-25 Dow Agrosciences Llc Use of picolinamide compounds with fungicidal activity
RU2702088C2 (ru) 2014-12-30 2019-10-03 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи Применение соединений пиколинамида в качестве фунгицидов
AU2021206286A1 (en) * 2020-01-10 2024-08-08 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (cg-RX-API-DMAC7.html) 1974-06-07 1981-03-18
JPS5432794A (en) 1977-08-18 1979-03-10 Omron Tateisi Electronics Co Manufacturing method of terminal rack
NO154918C (no) 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
ATE60571T1 (de) 1984-12-04 1991-02-15 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.
AU598775B2 (en) 1985-10-25 1990-07-05 Sandoz Ag Heterocyclic analogs of mevalonolactone
DE3543999A1 (de) 1985-12-13 1987-06-19 Bayer Ag Hochreine acarbose
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
HU205125B (en) 1987-05-22 1992-03-30 Squibb & Sons Inc Process for producing phosphorous compounds and pharmaceutical compositions comprising same
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9209628D0 (en) 1992-05-05 1992-06-17 Smithkline Beecham Plc Compounds
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
US5662934A (en) 1993-01-05 1997-09-02 Najarian; Thomas Compositions and methods for lowering cholesterol while maintaining antioxidant levels
DK0680320T3 (da) 1993-01-19 1999-10-25 Warner Lambert Co Stabilt oralt CI-981-præparat og fremgangsmåde til fremstilling deraf
US5801170A (en) 1993-12-07 1998-09-01 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5HT1D antagonists
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5698527A (en) 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
WO1997021993A2 (en) 1995-12-13 1997-06-19 The Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
IL117702A0 (en) 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
DE19622222A1 (de) 1996-06-03 1997-12-04 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikament zur Normalisierung der Serumlipide
AU2401697A (en) 1996-06-20 1998-01-07 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
CN1255043A (zh) 1997-05-08 2000-05-31 英国阿格里沃有限公司 杀真菌剂
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
MXPA00003546A (es) 1997-10-08 2002-08-06 Sankyo Co Compuesto heterociclico fusionado sustituido.
NZ508118A (en) 1998-07-06 2003-07-25 Bristol Myers Squibb Co Heteroaryl substituted biphenyl sulfonamides useful as dual angiotensin endothelin receptor antogonists
AU5612199A (en) 1998-09-10 2000-04-03 Forbes Medi-Tech Inc. Compositions comprising one or more phytosterols, phytostanols or mixtures of both and one or more alpha, beta, delta, or gamma tocotrienols or derivatives thereof and use of the compositions in treating or preventing cardiovascular disease, its underlying conditions and other
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
WO2000030665A1 (en) 1998-11-25 2000-06-02 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
AU776785B2 (en) 1999-02-24 2004-09-23 Johns Hopkins University, The Compositions and methods for modulating serum cholesterol
AU5031200A (en) 1999-05-28 2000-12-18 Vertex Pharmaceuticals Incorporated Method for preparing 5-substituted oxazoles
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
IL153645A0 (en) 2000-07-31 2003-07-06 Smithkline Beecham Plc Carboxamide compounds and their use as antagonists of a human 11cby receptor
WO2002101146A1 (fr) 2001-05-11 2002-12-19 Arina Nakayama Papier lumineux et son procede de production et d'utilisation
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
BR0213521A (pt) 2001-10-25 2004-10-19 Takeda Chemical Industries Ltd Composto, composição farmacêutica, agente farmacêutico, uso do composto, e, métodos para antagonizar um receptor de hormÈnio que concentra melanina em um mamìfero, para prevenir ou tratar uma doença causada por um hormÈnio que concentra melanina em um mamìfero, para prevenir ou tratar a obesidade em um mamìfero, para suprimir a entrada de alimento em um mamìfero, para prevenir ou tratar a depressão em um mamìfero, para prevenir ou tratar a ansiedade em um mamìfero e para produzir o composto
MXPA05006568A (es) 2002-12-20 2005-09-22 Pharmacia Corp Compuestos de pirazol aciclico para la inhibicion de proteina cinasa-2 activada por proteina cinasa activada por mitogenos.
EP1618112A1 (en) 2003-04-11 2006-01-25 SmithKline Beecham Corporation Heterocyclic mchr1 antagonists
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
AU2004285913A1 (en) 2003-10-23 2005-05-12 Glaxo Group Limited 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
US20050176738A1 (en) 2003-11-07 2005-08-11 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
US20050256124A1 (en) 2004-04-15 2005-11-17 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
RU2266906C1 (ru) 2004-04-29 2005-12-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека
US7745447B2 (en) 2005-10-26 2010-06-29 Bristol-Myers Squibb Company Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists

Also Published As

Publication number Publication date
US7989433B2 (en) 2011-08-02
JP2011521962A (ja) 2011-07-28
EA201001882A1 (ru) 2011-06-30
PE20091928A1 (es) 2009-12-31
CA2726264A1 (en) 2009-12-03
AU2009251331A1 (en) 2009-12-03
ZA201008451B (en) 2012-04-25
BRPI0913197A2 (pt) 2016-01-12
WO2009146365A1 (en) 2009-12-03
AR075260A1 (es) 2011-03-23
US20090298794A1 (en) 2009-12-03
MX2010012803A (es) 2010-12-07
CO6280492A2 (es) 2011-05-20
TW201000487A (en) 2010-01-01
EP2310394A1 (en) 2011-04-20
CN102099360A (zh) 2011-06-15
KR20110021988A (ko) 2011-03-04

Similar Documents

Publication Publication Date Title
ZA201008451B (en) Hydroxy substituted thieno pyrimidinones as melanin concentrating hormone receptor-1 antagonists
IL190898A0 (en) Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
IL213953A0 (en) Fused pyrimidines
SG11201401342VA (en) 5,7-substituted-imidazo[1,2-c]pyrimidines
IL201620A0 (en) Quinoline-carboxamide derivatives as p2y12 antagonists
SI2501704T1 (sl) Spojine spiropiperidina kot antagonisti oral-1 receptorja
IL215119A0 (en) Substitted fused pyrimidine compounds
IL210172A0 (en) Substituted pyrimidin-4-one derivatives
GB0816755D0 (en) Multifunctional antenna
IL206237A0 (en) Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
GB2473859B (en) Traffic pole
IL208072A0 (en) Traffic distribution control
EP2437601A4 (en) BIS-PYRIDYLPYRIDONE AS MELANIN CONCENTRATION HORMONE RECEPTOR-1 ANTAGONISTS
ZA201105419B (en) Stable growth hormone compounds
EP2437599A4 (en) BIS-PYRIDYLPYRIDONE AS MELANIN CONCENTRATION HORMONE RECEPTOR-1 ANTAGONISTS
EP2437598A4 (en) BIS-PYRIDYLPYRIDONES AS MELANGE-CONCENTRATION HORMONE RECEPTOR ANTAGONISTS
IL216330A0 (en) Anchoring post
EP2437600A4 (en) BIS-PYRIDYLPYRIDONE AS MELANIN CONCENTRATION HORMONE RECEPTOR-1 ANTAGONISTS
ZA201002171B (en) 2-s-benzyl substituted pyrimidines as crth2 antagonists
ZA201301561B (en) 5-ht2b receptor antagonists
IL210927A0 (en) 6-substituted benzoxazines as 5-ht-5a receptor antagonists
GB2469327B (en) Real-time traffic navigation
GB0816760D0 (en) Multifunctional antenna
GB0916521D0 (en) Improved weather radar
HK1154001A (en) Hydroxy substituted thieno pyrimidinones as melanin concentrating hormone receptor-1 antagonists